Cresco Labs (CRLBF) to Release Quarterly Earnings on Friday

Key Points

• Cresco Labs will report quarterly results before the market opens on Friday, May 8, with analysts forecasting EPS of -$0.04 and revenue of about $148.88 million.
• In the prior quarter Cresco posted EPS of -$0.02 (meeting estimates) and revenue of $164.04 million, but the company remains unprofitable with a negative return on equity (16.61%) and a net margin of -20.65%.
• The stock trades near $1.09 with a market cap around $548M and a negative P/E, while analyst coverage is light — Zacks moved the name from "strong sell" to "hold" and MarketBeat shows a consensus rating of "Buy."

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) will likely be posting its results before the market opens on Friday, May 8th. Analysts expect Cresco Labs to post earnings of ($0.04) per share and revenue of $148.8780 million for the quarter.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The business had revenue of $164.04 million for the quarter, compared to analyst estimates of $160.87 million. Cresco Labs had a negative return on equity of 16.61% and a negative net margin of 20.65%. On average, analysts expect Cresco Labs to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cresco Labs Stock Performance

OTCMKTS CRLBF opened at $1.09 on Friday. The stock has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $1.06. The company has a current ratio of 2.59, a quick ratio of 1.60 and a debt-to-equity ratio of 1.72. The stock has a market cap of $548.01 million, a PE ratio of -2.79 and a beta of 1.49. Cresco Labs has a twelve month low of $0.43 and a twelve month high of $2.30.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Cresco Labs from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy".

About Cresco Labs

Cresco Labs is a vertically integrated, multi-state cannabis operator in the United States. The company engages in the cultivation, manufacturing and distribution of a broad range of cannabis products, including flower, pre-rolled joints, concentrates, vaporizers, edibles and tinctures. Cresco Labs' operations span cultivation facilities, processing laboratories and a network of wholesale distribution centers that supply licensed dispensaries and retail outlets across key cannabis markets.

The company's product portfolio is organized under several branded platforms, such as MÜV, Reserve and High Supply, each designed to address different segments of the adult-use and medical cannabis markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.